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Abstract
Background: Simultaneous resection of both the liver and the pancreas carries significant complexity.
The objective of this study was to investigate peri-operative outcomes after a synchronous hepatec-
tomy and pancreatectomy (SHP).
Methods: The American College of Surgeons National Surgical Quality Improvement Project database
was queried to identify patients who underwent SHP. Resections were categorized as ‘< hemihepatec-
tomy’, ‘≥ hemihepatectomy’ (hemihepatectomy and trisectionectomy), ‘PD’ (pancreaticoduodenectomy
and total pancreatectomy) and ‘distal’ (distal pancreatectomy and enucleation).
Results: From 2005 to 2013, 480 patients underwent SHP. Patients were stratified based on the extent
of resection: ‘< hemihepatectomy + distal (n = 224)’, ‘≥ hemihepatectomy + distal’ (n = 49), ‘< hemihepa-
tectomy + PD’ (n = 83) and ‘≥ hemihepatectomy + PD’ (n = 24). Although the first three groups had a rea-
sonable and comparable safety profile (morbidity 33–51% and mortality 0–6.6%), the ‘≥ hemihepatectomy
+ PD’ group was associated with an 87.5% morbidity (organ space infection 58.3%, re-intubation 12.5%,
reoperation 25% and septic shock 25%), 8.3% 30-day mortality and 18.2% in-hospital mortality.
Conclusions: A synchronous hemihepatectomy (or trisectionectomy) with PD remains a highly morbid
combination and should be reserved for patients who have undergone extremely cautious selection.
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Introduction
Hepatic and pancreatic resections are complex operations
requiring considerable expertise. Early attempts at liver resec-
tion were fraught with mortality rates up to 20% owing to
parenchymal haemorrhage and liver failure.1 However,
advancements in peri-operative anaesthetic management,2 sur-
gical technique (including portal vein embolization),3 and
post-operative care have resulted in substantial improvements
in morbidity and mortality, with less than 5% mortality associ-
ated with a major hepatectomy in several recent studies.4–9
Similarly, for pancreaticoduodenectomy (PD) while morbidity
remains considerably high (41–52%),10–12 mortality has
improved from 25% to 1.7% in the last few decades.11–16
What remains controversial is the safety of synchronous
hepatectomy with pancreatectomy (SHP). Most studies
evaluating outcomes of SHP are limited to single institution
series. The first Japanese study on ‘hepato-pancreaticoduoden-
ectomy’ reported a 79% morbidity and 24% mortality in 24
patients with advanced hepatobiliary cancers.17 However, more
recent Japanese studies have shown a modest improvement in
post-operative morbidity and mortality after SHP.18,19 Ebata
et al.18 demonstrated a temporal reduction in mortality from
31% in the 1980s to 14% in the 2000s. While the short- and
long-term outcomes of SHP have been extensively studied in
Asia, there is a paucity of literature on outcomes of SHP in
the West. In 2004, Memorial Sloan Kettering reported an over-
all post-operative morbidity of 47% and post-operative mortal-
ity of 18% in 17 patients who underwent SHP for advanced
hepatobiliary cancers.20 More recently, Hemming et al.
revealed an overall morbidity of 35% and no peri-operative
deaths in 40 patients undergoing SHP.21 However, owing to
the small size and heterogeneous mix of surgical procedures in
these single-institution studies, the experience of SHP in the
West remains limited. Thus, the objective of this study was to
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determine the short-term outcomes of SHP in North America
using the American College of Surgeons National Surgical
Quality Improvement Program (ACS-NSQIP).
Patients and methods
The ACS-NSQIP Participant Use File was queried to identify all
patients who underwent any hepatic or pancreatic resections
from 1 January 2005 to 31 December 2013. The ACS-NSQIP is
a nationally validated, outcomes-based and risk-adjusted pro-
gramme used to measure and assess the quality of surgical care
in participating institutions. Initially introduced in 1991 to
assess post-operative morbidity and mortality in the Veteran
Affairs (VA) Health System, the success of the VA-NSQIP sub-
sequently led to the expansion of NSQIP into the private
sector. Currently, there are 569 sites enrolled in ACS-NSQIP,
which represents 10% of 5686 hospitals in the United States.
Trained and certified surgical clinical nurse reviewers prospec-
tively collect and report pre-, intra- and post-operative out-
comes on each patient into an electronic clinical registry.
Current procedural terminology (CPT) codes were used to
determine cases in which patients underwent both hepatic and
pancreatic resections. CPT code 47120 (partial lobectomy) was
classified as ‘< hemihepatectomy’. CPT codes 47122 (triseg-
mentectomy), 47125 (total left lobectomy) and 47130 (total
right lobectomy) were classified as ‘≥ hemihepatectomy’. CPT
codes 48120 (enucleation), 48140 (distal pancreatectomy),
48145 (distal pancreatectomy with pancreatojejunostomy) and
Table 1 Clinical characteristics
<Hemi-hepatectomy
+ Distal (n = 224)
≥Hemi-hepatectomy
+ Distal (n = 49)
<Hemi-hepatectomy
+ PD (n = 183)
≥Hemi-hepatectomy
+ PD (n = 24)
P-value
Age 58 (21–84) 58 (20–86) 64 (25–88) 53 (26–78) 0.001
Race
White 170 (75.9) 35 (71.4) 144 (78.7) 17 (70.8) 0.460
Black 26 (11.6) 5 (10.2) 12 (6.6) 2 (8.3)
Asian 9 (4.0) 3 (6.1) 14 (7.7) 2 (8.3)
Other 19 (8.5) 6 (12.2) 13 (7.1) 3 (12.5)
Female 129 (57.6) 24 (49) 191 (55.2) 9 (37.5) 0.232




45 (26.5) 6 (16.2) 37 (24.5) 3 (15.8) 0.528
Smoker 27 (12.1) 7 (14.3) 32 (17.5) 1 (4.2) 0.213
Diabetes 43 (19.2) 3 (6.1) 35 (19) 3 (12.5) 0.114
COPD 5 (2.2) 2 (4.1) 7 (3.8) 0 (0) 0.652
HTN on
medication
104 (46.4) 14 (28.6) 91 (49.7) 6 (25) 0.011
TIA (n = 273) 2 (1.6) 0 (0) 0 (0) 0 (0) 0.656
CVA (n-273) 1 (0.8) 0 (00 2 (1.9) 0 (0) 0.766








4 (3.2) 0 (0) 3 (1.9) 0 (0) 0.695
Creatinine 0.8 (0.3–2.4) 0.9 (0.4–1.6) 0.8 (0.3–2.43) 0.84 (0.6–1.3) 0.472
Albumin 3.9 (1–5.1) 3.9 (2–4.8) 3.8 (1.6–5) 3.8 (2.1–5.1) 0.109
Bilirubin 0.6 (0.1–2.2) 0.6 (0.1–8.9) 0.6 (0.6–11.5) 0.7 (0.1–8.9) <0.001
Platelet 228 (40–588) 225 (106–428) 250 (23–620) 278 (166–590) 0.011
INR 1 (0.8–1.9) 1 (0.8–1.7) 1 (0.74–9.1) 1 (0.91–1.2) 0.878
ASA
Class > 3
158 (70.5) 37 (75.5) 126 (68.9) 20 (83.3) 0.442
ASA, American Society of Anesthesiologist; TIA, transient ischaemic attack; HTN, hypertension; COPD, chronic obstructive pulmonary disease;
BMI, body mass index; CVA, cerebral vascular attack; INR, International normalized ratio.
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48146 (near total distal pancreatectomy) were classified as ‘dis-
tal pancreatectomy’. CPT codes 48150, 48152, 48153, 48154
(different versions of pancreaticoduodenectomy) and 48155
(total pancreatectomy) were categorized as ‘PD’. Patients who
underwent wedge biopsy of the liver (CPT 47100) were not
included in the study.
Categorical variables were presented as observed counts and
percentages and compared using Pearson’s chi-square and
Fisher’s exact test, where applicable. Continuous variables were
presented as the median and range compared using the
Student’s t-test for parametric variables and Wilcoxon’s rank-
sum test for non-parametric variables. Statistical analyses were
performed using SPSS version 22.0 (IBM, Chicago, IL, USA).
A two-sided P-value of < 0.05 was considered statistically
significant.
Results
Of the 48 568 hepatic and pancreatic resections performed
in participating ACS-NSQIP hospitals from 2005 to 2013,
480 (1%) resections were SHP. Patients were stratified into
four groups based on the extent of resection: < hemihepa-
tectomy with distal, ≥ hemihepatectomy with distal, < hemi-
hepatectomy with PD and ≥ hemihepatectomy with PD.
Patients who were selected to undergo ≥ hemihepatectomy
with PD were younger than patients in the other three
groups. Otherwise, there were no significant differences in
pre-operative clinical characteristics among the four groups
(Table 1).
Pre-operative indications for SHP based on the International
Statistical Classification of Diseases (ICD-9) codes are shown
in Table 2. Of the 480 patients in the entire cohort, 31% of
SHP cases were performed for pancreatic malignancy (not
otherwise specified), 21% specifically for neuroendocrine
tumours, 13% for secondary liver cancers and 8% for cholan-
giocarcinoma or gallbladder cancer.
Figure 1 demonstrates the rates of post-operative complica-
tions based on the extent of resection. As extent of resection
increased, post-operative morbidity was appreciably higher
(33%, 51%, 51.4% and 87.5%; P < 0.001), the operative time
was longer (270, 341, 385 and 461 min; P < 0.001), as was the
hospital length of stay (7.5, 8, 9 and 14 days; P < 0.001). Rates
of organ space infection (P < 0.001), post-operative bleeding
requiring a blood transfusion (P = 0.018), systemic sepsis
(P = 0.003), septic shock (P = 0.001) and re-operation
(P = 0.019) were significantly higher as an extent of the resec-
tion increased. The in-hospital mortality rates increased signifi-
cantly with extent of resection (2.4%, 0%, 6.4% and 18.2%;
P < 0.001), whereas the corresponding increase in 30-day mor-
tality only approached statistical significance (2.7%, 0%, 6.6%
and 8.3%, P = 0.054) (Fig. 2).
Discussion
Synchronous hepatectomy and PD is a procedure that is rarely
performed, accounting for only 1% of all hepatic and pancre-
atic cases in the United States. Worldwide, there are fewer than
400 cases reported from the East17,19,22–34 and 100 cases from
Table 2 Pre-operative diagnoses stratified by extent of hepato-pancreatectomy
<Hemi-hepatectomy
+ Distal (n = 224)
≥Hemi-hepatectomy
+ Distal (n = 49)
<Hemi-hepatectomy
+ PD (n = 183)
≥Hemi-hepatectomy
+ PD (n = 24)
Total (%)
Pancreatic malignancy 52 (23.2) 11 (22.4) 83 (45.4) 4 (16.7) 150 (31)
Neuroendocrine tumour 54 (24.2) 15 (30.6) 19 (10.4) 5 (20.8) 93 (19.3)
Secondary liver malignancy 40 (17.9) 11 (22.4) 13 (7.1) 0 (0) 64 (13.3)
Benign pancreatic disease 19 (8.5) 0 (0) 5 (2.7) 0 (0) 24 (5)
Bile duct malignancy 2 (0.9) 2 (4.1) 7 (3.8) 10 (41.7) 21 (4.4)
Gastric malignancy 17 (7.6) 1 (2.0) 1 (0.5) 0 (0) 19 (4)
Gallbladder malignancy 0 (0) 1 (2.0) 14 (7.7) 1 (4.2) 16 (3.3)
Colorectal malignancy 6 (2.7) 0 (0) 7 (3.8) 1 (4.2) 14 (2.9)
Ampullary malignancy 0 (0) 0 (0) 11 (6.0) 0 (0) 11 (2.3)
Duodenal malignancy 2 (0.9) 0 (0) 6 (3.3) 2 (8.3) 10 (2.1)
Primary liver malignancy 4 (1.8) 2 (4.1) 3 (1.6) 1 (4.2) 10 (2.1)
Retroperitoneal tumour 8 (3.6) 0 (0) 4 (2.2) 0 (0) 12 (1.5)
Benign biliary disease 4 (1.8) 1 (2.0) 1 (0.5) 0 (0) 6 (1.3)
Adrenal malignancy 1 (0.4) 0 (0) 0 (0) 0 (0) 1 (0.2)
Ovarian malignancy 1 (0.4) 0 (0) 0 (0) 0 (0) 1 (0.2)
Other 14 (6.3) 5 (10.2) 9 (4.9) 0 (0) 28 (5.8)
Total 224 49 183 24 480
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the West20,21,35–39 in the last 25 years. In the present study of
480 patients treated in North America, more extensive resec-
tions correlated with higher morbidity, longer hospital stay
and longer operative time. More specifically, ≥ hemihepatecto-
my (i.e. lobectomy or trisectionectomy) with PD was associ-
ated with profoundly higher morbidity of 87% and in-hospital
mortality of 18.2%. In contrast, we found that PD with
≤ hemihepatectomy was associated with a complication rate of
51.4% and in-hospital mortality rate of 6.4%.
A literature review of morbidity and mortality after being
combined PD with ≥ hemihepatectomy reveals variable short-
term results. Two studies from North America have described
outcomes after hepato-pancreaticoduodenectomy. A small study
of six patients revealed a morbidity of 83% and mortality of
50%.20 In contrast, another study of 40 patients who underwent
SHP, in general, demonstrated an overall mortality of 0% and
morbidity of 35% for the entire cohort; however, the exact num-
ber of patients who actually underwent ≥ hemihepatectomy with
PD could not be discerned. The Asian experience for hepato-
pancreaticoduodenectomy is more extensive and is summarized
in Table 3. The morbidity rates ranged from 57% to 95% while
the mortality rates ranged from 0% to 31%. This wide variation
in mortality rates in Asian centres merits further attention. A
careful review of these studies shows that the use of pre-opera-
tive portal vein embolization (PVE) prior to hepato-pancreatico-
duodenectomy is related to lower mortality rates in the range of
0 to 5%.18,30,31,33,34 In contrast, in the two studies that did not
employ PVE, the mortality rates were significantly higher (21%
to 31%).19,32 Although cross-study comparisons are limited to
securing definitive conclusions, it appears that pre-operative
portal vein embolization can be an effective way to decrease
post-operative liver failure and mortality after SHP.
Long-term survival outcomes after SHP for advanced hepa-
tobiliary malignancies remain unclear. A review of Table 3
shows SHP for gallbladder cancer is associated with 5-year
survival rates between 0% and 25%,19,32–34 whereas SHP for
cholangiocarcinoma has been associated with 5-year survival
rates ranging from 12% to 54%.19,30,32,34 In contrast, SHP for
more indolent malignancies such as neuroendocrine tumors is
associated with more favourable 5-year survival rates ranging
Figure 1 Morbidity of the entire cohort stratified by extent of resection
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from 64% to 69%.35,40 The superior long-term outcomes asso-
ciated with aggressive resection of neuroendocrine tumours
may justify performing SHP in this group. Given the lack of
favourable long-term survival outcomes, selection of patients
with gallbladder cancer and cholangiocarcinoma for hepato-
pancreaticoduodenectomy remains extremely challenging.
The present study has several important limitations. First,
ACS-NSQIP is a national clinical registry that obtains only
Figure 2 Mortality of the entire cohort stratified by extent of resection
Table 3 Selected publications reporting outcomes of hepato-pancreaticoduodenectomy
Series Number of patients Morbidity Mortality Fraction of patients who
underwent preoperative PVE
5 year OS
Miwa et al.33 26 30.8% 0% 77% 25% (GBC)
51.9% (BDC)
Wakai et al.19 28 82% 21% 0 9% (GBC)
12%(BDC)
Kaneoka et al.31 14 57% 0% 43% 50%
Ebata et al.30 78 77% 2.4% 79% 54% (BDC)
Lim et al.32 23 91% 31% 0 10% (GBC)
32.3% (BDC)
Sakamoto et al.34 19 95% 5% 89% 0% (GBC)
53% (BDC)
PVE, portal vein embolization; GBC, gallbladder cancer; BDC, bile duct cancer; OS, overall survival.
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30-day post-operative outcomes. This limits our ability to
detect mortality after 30 days, particularly as 90-day mortality
is currently considered a more reliable metric of surgical out-
comes.41 Second, ACS-NSQIP lacks detailed pathology data
(exact diagnosis, margin, grade and lymph node status) as well
as long-term oncologic data (recurrence and survival) that
would have provided further insight into the selection of
patients for this extensive procedure. Third, specific hepatec-
tomy and pancreatectomy complications could not be deci-
phered using the ACS-NSQIP database. For example, although
‘organ space infection’ is available in the database, it remains
unclear if this complication is representative of a pancreatic
fistula, bile leak or another source of intra-abdominal abscess.
Along the same lines, post-hepatectomy liver failure is not cap-
tured in the ACS-NSQIP database. Lastly, although PVE
appears critical in decreasing mortality after hepato-pancreati-
coduodenectomy, we could not assess the effect of PVE using
ACS-NSQIP. Nevertheless, the use of this large and multi-insti-
tutional registry provides useful and generalizable insight on
the outcomes of SHP in North American patients.
In conclusion, less extensive combined pancreatic and hepatic
resections can be performed with reasonable morbidity and
mortality, with the exception of combined PD with hemihepa-
tectomy, which is associated with almost universal morbidity
(87%) and considerable in-hospital mortality (18%). Patients
should be selected for this extensive procedure with extreme
caution when surgical candidacy is robust, and the long-term
oncological benefit is anticipated to outweigh the peri-opera-
tive risks significantly. This appears to be the case more com-
monly for patients with a pancreatic neuroendocrine tumour
with liver metastases and less so for patients with biliary tract
adenocarcinoma. Furthermore, although not supported directly
from our data, a review of the literature suggests that
pre-operative PVE might decrease the incidence of mortality
after hepato-pancreaticoduodenectomy. The role of PVE in
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